^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dapansutrile (OLT1177)

    i
    Other names: OLT1177, OLT-1177
    Associations

    News

    Trials
    Company:
    Olatec Therap
    Drug class:
    NLRP3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    18d
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Aug 2026 --> Jan 2027 | Trial primary completion date: Jul 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    19d
    Targeting NLRP3 inflammasome: a novel strategy for improving immune checkpoint inhibitor-associated pneumonitis. (PubMed, Transl Lung Cancer Res)
    Therapeutic interventions with NLRP3 inflammasome inhibitors (MCC950 and dapansutrile) and a macrophage-depleting agent (clodronate liposomes) were evaluated by micro-computed tomography (CT), histopathology, and serum inflammatory cytokine assays. The findings revealed: (I) significant upregulation of NLRP3 inflammasome pathway-related genes and downstream factors (IL-1β, IL-18) in CIP mouse lungs, alongside increased macrophage infiltration; (II) pneumonitis injury was markedly alleviated and serum inflammatory cytokine levels were reduced by both NLRP3 inflammasome inhibition and macrophage depletion; (III) dapansutrile downregulated NLRP3 expression via inhibition of the NF-κB pathway; (IV) enriched macrophage subpopulations (Mac-IL1B) expressing high levels of NLRP3 were identified in CIP patients. This study provides the first evidence that NLRP3 inflammasome activation constitutes a key upstream mechanism in CIP pathogenesis, offering novel therapeutic strategies for targeted intervention.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    clodronate disodium • dapansutrile (OLT1177)
    30d
    DAPA-PD: A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease (clinicaltrials.gov)
    P2, N=36, Recruiting, Cambridge University Hospitals NHS Foundation Trust | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CRP (C-reactive protein)
    |
    dapansutrile (OLT1177)
    3ms
    Dapansutrile in multidisciplinary therapeutic applications: mechanisms and clinical perspectives. (PubMed, Front Pharmacol)
    Furthermore, dapansutrile exhibits synergistic effects when combined with agents such as lonafarnib or immune checkpoint inhibitors, enhancing anti-inflammatory and anti-tumor responses. This review consolidates evidence on dapansutrile's molecular mechanisms, therapeutic applications, and biosafety, highlighting its potential as a novel, well-tolerated, and versatile anti-inflammatory agent. Future research should focus on optimizing its delivery, particularly to the central nervous system, and leveraging artificial intelligence to predict effective drug combinations.
    Review • Journal
    |
    IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    dapansutrile (OLT1177)
    3ms
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    7ms
    DAPA-PD: A Trial to Test the Use of Dapansutrile, an Anti-inflammatory Medication, in People With Parkinson's Disease (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Cambridge University Hospitals NHS Foundation Trust
    New P2 trial
    |
    dapansutrile (OLT1177)
    10ms
    Multimodality Cardiovascular Imaging for the Translation of Therapies for Vascular Activation After MI (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, University of Virginia | Trial completion date: Oct 2028 --> Jan 2029 | Trial primary completion date: Dec 2027 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    10ms
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Oct 2025 --> Dec 2025
    Trial completion date
    |
    dapansutrile (OLT1177)
    over1year
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Dec 2025 --> Oct 2025 | Trial primary completion date: Nov 2025 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    over1year
    Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare (clinicaltrials.gov)
    P2/3, N=300, Recruiting, Olatec Therapeutics LLC | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    dapansutrile (OLT1177)
    over1year
    Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia (clinicaltrials.gov)
    P2, N=300, Recruiting, University Hospital, Basel, Switzerland | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CRP (C-reactive protein)
    |
    dapansutrile (OLT1177)
    almost2years
    A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma (clinicaltrials.gov)
    P1/2, N=26, Recruiting, April Salama, M.D. | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Keytruda (pembrolizumab) • dapansutrile (OLT1177)